<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407105</url>
  </required_header>
  <id_info>
    <org_study_id>MDX010-10</org_study_id>
    <nct_id>NCT03407105</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>This trial was conducted by the previous sponsor, Medarex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010
      in HIV-infected subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2003</start_date>
  <completion_date type="Actual">February 21, 2006</completion_date>
  <primary_completion_date type="Actual">February 21, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment induced dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 141 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of treatment induced DLTs</measure>
    <time_frame>Up to 141 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment emergent AEs (adverse events)</measure>
    <time_frame>Up to 141 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration observed post-dose (Cmax)</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentration observed post-dose (Tmax)</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Ribonucleic Acid (RNA) level</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 (cluster of differentiation) T (thymus) cell cytokine responses to Human Immunodeficiency Virus-1 (HIV-1) antigens</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 T cell cytokine responses to Candida antigen</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 T cell cytokine responses to tetanus antigen</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 (cluster of differentiation) T cell cytokine responses to HIV-1 antigens</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 T cell cytokine responses to Candida antigen</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 T cell cytokine responses to tetanus antigen</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Proliferation Assay (LPA) to HIV-1 antigens</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPA to Candida antigens</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPA to tetanus antigens</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tetanus toxin antibody level</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD4 T cells</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD8 T cells</measure>
    <time_frame>Up to 141 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDX-010</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Ipilimumab</other_name>
    <other_name>BMS-734016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Detectable HIV viremia (HIV-1 RNA level between 1,000 and 100,000 copies/mL)

          -  CD4 count greater than or equal to 100 cells/mm3

          -  Current antiretroviral therapy regimen following at least 2 previous changes for
             documented virologic failure

          -  Documented resistance tests demonstrating the presence of at least 1 mutation to each
             major therapeutic class of antiretroviral therapy

          -  No significant organ compromise

        Exclusion Criteria:

          -  Initiation of any new medications that might reasonably affect the immune response or
             viral load within 4 weeks prior to screening

          -  Tetanus booster immunization within 2 months of screening, or a history of anaphylaxis
             or severe local reaction to the tetanus vaccine

          -  History of autoimmune disease at risk for recurrence

          -  Current malignancy, except Stage A or B cervical carcinoma or basal cell carcinoma

          -  Chronic viral hepatitis, due to Hepatitis B or Hepatitis C undergoing current
             treatment or Hepatitis B DNA greater than 25 pg/cc or Hepatitis C RNA greater than
             20,000 IU/cc

          -  Currently undergoing treatment or prophylaxis for tuberculosis infection

          -  Chronic active infectious disease (other than HIV)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower ID Medical Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Resource</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shannon Schrader, MD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

